FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2599149176> ?p ?o ?g. }

• W2599149176 abstract "18118 Background: Skin rash is the most common toxicity of EGFR-targeted therapy. Skin rash of EGFR inhibitor is associated with longer survival or tumor response. However, the clinical and genetic factors associated with this skin rash are not well understood. Methods: Fifty-two non-small-cell lung cancer patients enrolled in a prospective clinical trial of first-line gefitinib treatment were genotyped for EGFR intron 1 CA repeat polymorphism (CAn) and single nucleotide polymorphisms at promoters G-216T, C-191A, and R521K. Grade 2 to 3 skin rash within 4 weeks of treatment (early G2/3 rash) was correlated with the genotype and clinicopathological features of the patients by multivariate logistic regression. Results: Seventeen patients (32.7%) developed early G2/3 rash. In multivariate logistic regression analysis, only the CAn genotype was associated with early G2/3 rash and the effect was modified by patient age. Early G2/3 rash developed in 21% of patients with homozygous long allele (19 to 22 repeats, L) genotype (4/19), 31% of heterozygous short allele (15 to 18 repeats, S) / L genotype (8/26), and 71% of S/S genotype (5/7), respectively. The median ages of patients with early G2/3 rash and patients without early G2/3 rash were 57 years (range: 39–77) and 69 years (range: 43–86), respectively. The estimated logarithm of odds ratio (ln OR) for early G2/3 rash, as compared to S/S genotype, for S/L genotype was -0.038 multiplied by patient age (P = 0.011); and the ln OR for L/L genotype was -0.050 multiplied by patient age (P = 0.004). Fifty patients were evaluable for response. In logistic regression analysis, early G2/3 rash correlated with tumor response (P = 0.027). However, the CAn genotype was not significantly correlated with tumor response (P = 0.43). Conclusions: Homozygous short allele of EGFR CAn is more likely to develop skin rashes on gefitinib treatment. Genotyping of EGFR CAn appears to be a useful predictive marker for development of skin rashes on gefitinib use. [Table: see text]" @default.
• W2599149176 created "2017-04-07" @default.
• W2599149176 creator A5006081383 @default.
• W2599149176 creator A5006754529 @default.
• W2599149176 creator A5015023254 @default.
• W2599149176 creator A5036989840 @default.
• W2599149176 creator A5056377615 @default.
• W2599149176 creator A5058076881 @default.
• W2599149176 creator A5064321949 @default.
• W2599149176 creator A5079289736 @default.
• W2599149176 creator A5087541034 @default.
• W2599149176 date "2007-06-20" @default.
• W2599149176 modified "2023-09-27" @default.
• W2599149176 title "The association of epidermal growth factor receptor (EGFR) polymorphisms and clinicopathological factors with skin rash on gefitinib use" @default.
• W2599149176 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.18118" @default.
• W2599149176 hasPublicationYear "2007" @default.
• W2599149176 type Work @default.
• W2599149176 sameAs 2599149176 @default.
• W2599149176 citedByCount "0" @default.
• W2599149176 crossrefType "journal-article" @default.
• W2599149176 hasAuthorship W2599149176A5006081383 @default.
• W2599149176 hasAuthorship W2599149176A5006754529 @default.
• W2599149176 hasAuthorship W2599149176A5015023254 @default.
• W2599149176 hasAuthorship W2599149176A5036989840 @default.
• W2599149176 hasAuthorship W2599149176A5056377615 @default.
• W2599149176 hasAuthorship W2599149176A5058076881 @default.
• W2599149176 hasAuthorship W2599149176A5064321949 @default.
• W2599149176 hasAuthorship W2599149176A5079289736 @default.
• W2599149176 hasAuthorship W2599149176A5087541034 @default.
• W2599149176 hasConcept C126322002 @default.
• W2599149176 hasConcept C143998085 @default.
• W2599149176 hasConcept C16005928 @default.
• W2599149176 hasConcept C170493617 @default.
• W2599149176 hasConcept C2776362946 @default.
• W2599149176 hasConcept C2777506169 @default.
• W2599149176 hasConcept C2778570526 @default.
• W2599149176 hasConcept C2779438470 @default.
• W2599149176 hasConcept C2780580887 @default.
• W2599149176 hasConcept C502942594 @default.
• W2599149176 hasConcept C71924100 @default.
• W2599149176 hasConceptScore W2599149176C126322002 @default.
• W2599149176 hasConceptScore W2599149176C143998085 @default.
• W2599149176 hasConceptScore W2599149176C16005928 @default.
• W2599149176 hasConceptScore W2599149176C170493617 @default.
• W2599149176 hasConceptScore W2599149176C2776362946 @default.
• W2599149176 hasConceptScore W2599149176C2777506169 @default.
• W2599149176 hasConceptScore W2599149176C2778570526 @default.
• W2599149176 hasConceptScore W2599149176C2779438470 @default.
• W2599149176 hasConceptScore W2599149176C2780580887 @default.
• W2599149176 hasConceptScore W2599149176C502942594 @default.
• W2599149176 hasConceptScore W2599149176C71924100 @default.
• W2599149176 hasLocation W25991491761 @default.
• W2599149176 hasOpenAccess W2599149176 @default.
• W2599149176 hasPrimaryLocation W25991491761 @default.
• W2599149176 hasRelatedWork W1965926387 @default.
• W2599149176 hasRelatedWork W1997605441 @default.
• W2599149176 hasRelatedWork W2015874289 @default.
• W2599149176 hasRelatedWork W2070232725 @default.
• W2599149176 hasRelatedWork W2074938547 @default.
• W2599149176 hasRelatedWork W2357703221 @default.
• W2599149176 hasRelatedWork W2591174332 @default.
• W2599149176 hasRelatedWork W2600570766 @default.
• W2599149176 hasRelatedWork W2755482548 @default.
• W2599149176 hasRelatedWork W3034543458 @default.
• W2599149176 isParatext "false" @default.
• W2599149176 isRetracted "false" @default.
• W2599149176 magId "2599149176" @default.
• W2599149176 workType "article" @default.